Radiation dosimetry results for zevalin radioimmunotherapy of rituximab-refractory non-hodgkin lymphoma

This publication has 6 references indexed in Scilit:

• Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin™ radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
  Critical Reviews in Oncology/Hematology, 2001
• Phase I/II 90 Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma
  European Journal of Nuclear Medicine and Molecular Imaging, 2000
• Phase I/II Trial of IDEC-Y2B8 Radioimmunotherapy for Treatment of Relapsed or Refractory CD20⁺B-Cell Non-Hodgkin's Lymphoma
  Journal of Clinical Oncology, 1999
• Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
  Blood, 1994
• Expression of human B cell-associated antigens on leukemias and lymphomas: a model of human B cell differentiation
  Blood, 1984
• Radioactive decay data tables
  Published by Office of Scientific and Technical Information (OSTI) ,1981